Novartis ordered by US District Court to pay $177.8 million to Daiichi Sankyo for Tafinlar patent violation.
A US district court has ruled that Tafinlar (dabrafenib) infringes two US patents owned by Daiichi Sankyo’s now-defunct Plexxikon unit, ordering a payment of $177.8 million.
Plexxikon, which was closed in March 2022, had sued Novartis at the US District Court for the Northern District of California in August 2017, claiming that Tafinlar contravenes its patents. In its ruling, the court awarded Plexxikon $177.8 million in damages and additional 9% royalties for future US sales of Tafinlar until the patents expire. However, the court found that the patent violation was not willful.
Tafinlar and its combination drug Mekinist (trametinib) collectively generated sales of $606 million in the US in 2021. Plexxikon discontinued operations at the end of March 2022 after transferring all R&D assets and marketed products to the Daiichi Sankyo group.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins